Need for Ethical Governance on the Implementation and Use of Patient-derived Xenograft (PDX) Models for Anti-cancer Drug Discovery and Development: Ethical Considerations and Policy Proposal

Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors...

Full description

Saved in:
Bibliographic Details
Published inJMA Journal Vol. 7; no. 4; pp. 605 - 609
Main Authors Yagishita, Shigehiro, Matsui, Kenji, Hamada, Akinobu
Format Journal Article
LanguageEnglish
Published Japan Japan Medical Association / The Japanese Associaiton of Medical Sciences 15.10.2024
Japan Medical Association
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.
AbstractList Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.
Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.
Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.
Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently considered the most reliable preclinical models that quite accurately stimulate the real-world characteristics and microenvironments of tumors in patients. The ethical uniqueness of the PDX model, which lies in the fact that it is a hybrid of living human tumor tissue and a carrier mouse, raises several ethical concerns. This study presents four ethical points for consideration and a model ethical governance policy for the implementation and use of PDX models for research. First, PDX models carrying living tumor tissues originating from individual patients with dignity must be treated ethically as materials and data in compliance with the principle of respect for persons. Second, although PDX models themselves are patentable and can be commercialized, it is a standard view, as represented by the Oviedo Convention by the Council of Europe, that those living tumor tissues carried by PDX models shall not give rise to financial gain since those tissues are human body parts; therefore, they should be treated according to a recent ethical approach with the custodianship model as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of PDX models for research purposes must comply with national and international regulations on both animal experimentation and human subject research. These four points should be carefully examined and properly institutionalized as an ethical governance policy in each institution that plans on utilizing or implementing PDX models for research.
Author Hamada, Akinobu
Yagishita, Shigehiro
Matsui, Kenji
Author_xml – sequence: 1
  fullname: Yagishita, Shigehiro
  organization: Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
– sequence: 1
  fullname: Matsui, Kenji
  organization: Division of Bioethics and Healthcare Law, National Cancer Center Institute for Cancer Control, Tokyo, Japan
– sequence: 1
  fullname: Hamada, Akinobu
  organization: Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39513080$$D View this record in MEDLINE/PubMed
BookMark eNpVUk1v1DAUjFARLaVnbsjHckjrjyQ4CAlVu22pVGAPVNqb5Tgvu145drC9K-2f47fh7LYRHCxb8-bNPPnN2-zEOgtZ9p7gK0aqil5verm5opiyHJO6fpWd0YKxnNGan0xvvjzNLkLYYIxpTSnn5E12yuqSMMzxWfbnB0CLOufRbVxrJQ26dzvwVloFyFkU14Ae-sFADzbKqBMkbYueQqp2aJGQhOcteL1LOkuwbuVlF9HlYr78iL67Fkw4yN_YqHM1yno099sVmuugRqv9QXAOOzBuGF0-T6PMnA06aR98w4G3cEarPVp4N7ggzbvsdSdNgIvn-zx7urv9NfuWP_68f5jdPOaqKIuY85pB3eGOlVWDVdXwDuOGMuhkyyQvGgbAK1ynV4uBlA1uyppjWjUtV5y0ip1nX4-6w7bpoVVpTC-NGLzupd8LJ7X4v2L1WqzcThBSpj2wIilcPit493sLIYo-fQAYIy24bRCMUM4ow4Qn6od_zSaXl60lwvWRoLwLwUM3UQgWh2iIMRpijIYYo5E6vhw7NiHKFUx86aNWBo70T6JIp8LlBKu19AIs-wszD8Z3
ContentType Journal Article
Copyright 2024 Japan Medical Association
Copyright © Japan Medical Association.
Copyright © Japan Medical Association
Copyright_xml – notice: 2024 Japan Medical Association
– notice: Copyright © Japan Medical Association.
– notice: Copyright © Japan Medical Association
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.31662/jmaj.2023-0199
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2433-3298
EndPage 609
ExternalDocumentID PMC11543334
39513080
10_31662_jmaj_2023_0199
article_jmaj_7_4_7_605_article_char_en
Genre Journal Article
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
JSF
JSH
OK1
PGMZT
RJT
RPM
RZJ
AAYXX
CITATION
NPM
7X8
5PM
ID FETCH-LOGICAL-c454t-893e9f0f356b0c6b8f00b23efad3a84b3ee860984bd0e15b0b598026bd8c81dc3
ISSN 2433-328X
2433-3298
IngestDate Thu Aug 21 18:30:06 EDT 2025
Thu Jul 10 22:06:27 EDT 2025
Mon Jul 21 06:07:19 EDT 2025
Tue Jul 01 02:28:49 EDT 2025
Wed Sep 03 06:30:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords trust
patient-derived xenograft model
research ethics
ethical governance policy
Language English
License https://creativecommons.org/licenses/by/4.0
Copyright © Japan Medical Association.
JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by/4.0/).
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c454t-893e9f0f356b0c6b8f00b23efad3a84b3ee860984bd0e15b0b598026bd8c81dc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Corresponding author: Kenji Matsui, kematsui@ncc.go.jp
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC11543334
PMID 39513080
PQID 3128323018
PQPubID 23479
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11543334
proquest_miscellaneous_3128323018
pubmed_primary_39513080
crossref_primary_10_31662_jmaj_2023_0199
jstage_primary_article_jmaj_7_4_7_605_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-10-15
PublicationDateYYYYMMDD 2024-10-15
PublicationDate_xml – month: 10
  year: 2024
  text: 2024-10-15
  day: 15
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle JMA Journal
PublicationTitleAlternate JMA J
PublicationYear 2024
Publisher Japan Medical Association / The Japanese Associaiton of Medical Sciences
Japan Medical Association
Publisher_xml – name: Japan Medical Association / The Japanese Associaiton of Medical Sciences
– name: Japan Medical Association
References 5. Toya W, Yamamoto K, Aizawa K, et al. Paid-for transfer of human samples in research biobanks and the applicability of charitable trusts. Jpn J Clin Pharmacol Ther. 2022;54 (1):29-36. Japanese.
1. Gamo NJ, Birknow MR, Sullivan D, et al. Valley of death: a proposal to build a "translational bridge" for the next generation. Neurosci Res. 2017;115:1-4.
4. Yassin R, Lockhart N, del Riego MG, et al. Custodianship as an ethical framework for biospecimen-based research. Cancer Epidemiol Biomarkers Prev. 2010;19 (4):1012-5.
3. Ledford H. US cancer institute overhauls cell lines. Nature. 2016;530 (7591):391.
2. Liu Y, Wu W, Cai C, et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8 (1):160.
References_xml – reference: 3. Ledford H. US cancer institute overhauls cell lines. Nature. 2016;530 (7591):391.
– reference: 5. Toya W, Yamamoto K, Aizawa K, et al. Paid-for transfer of human samples in research biobanks and the applicability of charitable trusts. Jpn J Clin Pharmacol Ther. 2022;54 (1):29-36. Japanese.
– reference: 4. Yassin R, Lockhart N, del Riego MG, et al. Custodianship as an ethical framework for biospecimen-based research. Cancer Epidemiol Biomarkers Prev. 2010;19 (4):1012-5.
– reference: 1. Gamo NJ, Birknow MR, Sullivan D, et al. Valley of death: a proposal to build a "translational bridge" for the next generation. Neurosci Res. 2017;115:1-4.
– reference: 2. Liu Y, Wu W, Cai C, et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8 (1):160.
SSID ssj0002922881
Score 2.2780764
Snippet Patient-derived xenograft (PDX) models, in which tumor tissues resected from cancer patients are transplanted into immunocompromised mice, have been recently...
SourceID pubmedcentral
proquest
pubmed
crossref
jstage
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 605
SubjectTerms ethical governance policy
Opinion
patient-derived xenograft model
research ethics
trust
Title Need for Ethical Governance on the Implementation and Use of Patient-derived Xenograft (PDX) Models for Anti-cancer Drug Discovery and Development: Ethical Considerations and Policy Proposal
URI https://www.jstage.jst.go.jp/article/jmaj/7/4/7_605/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/39513080
https://www.proquest.com/docview/3128323018
https://pubmed.ncbi.nlm.nih.gov/PMC11543334
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX JMA Journal, 2024/10/15, Vol.7(4), pp.605-609
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKQIgXxJ1wk5F4GJqypbGTJrxNG2hC6lSJVepbFCdOm8KSqW2Q4MfxI_hFnGMnrlP2AHtoVLmu7eR88bn4XAh5B89dZiwbuiJkhct9UbhxIJgbs5Tl2QgE5hwDhcfn4dmUf54Fs8Hgt-W11GzEYfbz2riSm1AV2oCuGCX7H5Q1g0IDfAf6whUoDNd_ovE5sB7lJ6i81uFh68q5KgpAHwLo7L-XbYCRdjyeavP9RGdUdXNY6XcYZyYrdNXSBXompzO0F2CltG8qYwNmGSjdDIdeHZyumjnm7cxwuh-tN7NxPkIjQ7egrh5o63CnQhNUJmKMULiq1-0ddtLx-PjAvnFlKd-sm7KNIFqWZpNK52g806Lvl0U5l4tyVVvm-DTXBuOvZVWLxrZt-ByZgo7u1HwH5IXtidUuXtUm6XPGXOar8sTAz-w2Xd262-VHFpi5tWOHXmAx_1DlaviLr7BhGGKi2uVlujzEgvMuSMbxloUax8bJ-ATzGzHG-C1y2wfVxbcsSCgd-LHvR6p2rlm6zjil5jjqz9ATlu4sQV-Yy-tUoV2PXktEunhA7re6DT3WQH1IBrJ6RO6OW--Nx-QX4pUCmGgLD7rFK60rCnilfbxSAAwFvNK6oDt4pQavdB_Q-p5qrKrhLaxSxCo1WFUDWlj9YJbSR6rqp5FKO6Q-IdNPHy9Ozty2foib8YBvXBDFZVx4BQtC4WWhiArPEz6TRZqzNOKCSRkBweFb7slhIDwRxJHnhyKPMlDjMvaU7FV1JZ8TygoGgjHmRWAFz1IpUjy_HI7kiIN0FzCH7HeESq50mpgE1GtF0wRpmiBNE6SpQwJNSNOx3T90v1HC4QOoNM0Yfgm7nUPednRPgAXguV5aybpZwyxYbww4deSQZxoHZmwGGhQDrdAhUQ8hpgOml-__UpULlWa-A_KLm__1Jbm3fa1fkb3NqpGvQYjfiDfqrfgDuen-GQ
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Need+for+Ethical+Governance+on+the+Implementation+and+Use+of+Patient-derived+Xenograft+%28PDX%29+Models+for+Anti-cancer+Drug+Discovery+and+Development%3A+Ethical+Considerations+and+Policy+Proposal&rft.jtitle=JMA+journal&rft.au=Matsui%2C+Kenji&rft.au=Yagishita%2C+Shigehiro&rft.au=Hamada%2C+Akinobu&rft.date=2024-10-15&rft.pub=Japan+Medical+Association&rft.issn=2433-328X&rft.eissn=2433-3298&rft.volume=7&rft.issue=4&rft.spage=605&rft.epage=609&rft_id=info:doi/10.31662%2Fjmaj.2023-0199&rft.externalDocID=PMC11543334
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2433-328X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2433-328X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2433-328X&client=summon